Incorporating FLT3 inhibitors into acute myeloid leukemia treatment regimens.

Incorporating FLT3 inhibitors into acute myeloid leukemia treatment regimens. Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

Incorporating FLT3 inhibitors into acute myeloid leukemia treatment regimens. Abstract Text:

FMS-Like-Tyrosine kinase-3 (FLT3) mutations are found in about 30% of cases of acute myeloid leukemia and confer an increased relapse rate and reduced overall survival. Targeting of this tyrosine kinase by direction inhibition is the focus of both preclinical and clinical research in AML. Several molecules in clinical development inhibit FLT3 with varying degrees of specificity. Preclinical models suggest that these compounds enhance the cytotoxicity of conventional chemotherapeutics against FLT3 mutant leukemia cells. The pharmacodynamic interactions between FLT3 inhibitors and chemotherapy appear to be sequence dependent. When the FLT3 inhibitor is used prior to chemotherapy, antagonism is displayed, while if FLT3 inhibition is instituted after to exposure to chemotherapy, synergistic cytotoxicity is seen. The combination of FLT3 inhibitors with chemotherapy is also complicated by potential pharmacokinetic obstacles, such as plasma protein binding and p-glycoprotein interactions. Ongoing and future studies are aimed at incorporating FLT3 inhibitors into conventional induction and consolidation therapy specifically for patients with FLT3 mutant AML.

Incorporating FLT3 inhibitors into acute myeloid leukemia treatment regimens. Publishing Authors By Initials

For similar abstracts research abstracts see: abstracts research

PUBMED ID PMID:

MEDLINE DATE:

Incorporating FLT3 inhibitors into acute myeloid leukemia treatment regimens. Journal Published:

PUBLICATION TYPE: Journal Article

Journal: Leukemia & lymphoma

VOLUME: 49

Page Numbers: 852-63

Journal Abbreviation: Leuk. Lymphoma

ISSN: 1029-2403

DAY: 8

MONTH: May

YEAR: 2008

Incorporating FLT3 inhibitors into acute myeloid leukemia treatment regimens. Information

Number of References:

LANGUAGE: eng

NlmUniqueID: 9007422

Incorporating FLT3 inhibitors into acute myeloid leukemia treatment regimens. Keywords Mesh Terms:

KEYWORDS:

MESH TERMS:

Chemical & Substance for Abstract: Incorporating FLT3 inhibitors into acute myeloid leukemia treatment regimens. Information

Substance Name:

Registry Number:

Grant and Affiliation Information for Incorporating FLT3 inhibitors into acute myeloid leukemia treatment regimens.

AFFILIATION: Division of Hematologic Malignancies, Department of Oncology, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD, USA.

Country: England

AGENCY:

GRANT:

ACRONYM:

MEDLINETA: Leuk Lymphoma

REFSOURCE:

DATABASENAME:

ACCESSION NUMBER:

Number Hits: 0

Incorporating FLT3 inhibitors into acute myeloid leukemia treatment regimens Related Publications

• A Botrytis cinerea Emopamil Binding Domain Protein, Required for Full Virulence, Belongs to a Eukaryotic Superfamily Which Has Expanded in Euascomycetes.
• ABVD plus radiotherapy versus EVE plus radiotherapy in unfavorable stage IA and IIA Hodgkin's lymphoma: results from an Intergruppo Italiano Linfomi randomized study.
• Adaptive reshaping of objects in (multiparameter) Hilbert space for enhanced detection and classification: an application of receiver operating curve statistics to laser-based mass spectroscopy.
• Characterization of summer infertility of sows in large confinement units.
• Developmental and tissue-specific accumulation pattern for the Drosophila melanogaster TART ORF1 protein.
• Effect of altering suckling intervals of early-weaned pigs on rebreeding performance of sows.
• Erythrokeratoderma variabilis.
• Evaluation of delayed-type hypersensitivity in patients with suspected immunodeficiency.
• Fabrication of patch pipets.
• Hypovitaminosis d in the elderly: from bone to brain.
• Identification of multiple transcription initiation, polyadenylation, and splice sites in the Drosophila melanogaster TART family of telomeric retrotransposons.
• Identification of novel hsp65 RFLPs for Mycobacterium leprae.
• Incorporating FLT3 inhibitors into acute myeloid leukemia treatment regimens.
• LIPID BIOSYNTHESIS BY HUMAN BONE MARROW CELL CULTURES AND GAMMA RADIATION.
• Leprosy as Immune Reconstitution Inflammatory Syndrome in HIV-positive Persons.
• Molecular origin of endemic leprosy in New York City.
• Phase matching in femtosecond BOXCARS.
• Positron emission tomography in the staging of patients with Hodgkin's lymphoma. A prospective multicentric study by the Intergruppo Italiano Linfomi.
• Quantitative spectrographic analysis of blood and tissue fluids.
• [Measurement of arterial oxyhemoglobin saturation in congenital and acquired heart disease.]